A ‘futile’ fatty acid cycle as central mediator and exploitable target in cancer resistance to molecular targeted therapy
FWO-SB-Beurs: Nanobodies targeting mutant-EGFR as a unique tumor-restrictive vehicle for targeted therapy of glioblastoma
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy
Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model
Imaging the invisible in preclinical models using magnetic particle imaging (MPI Magnetic Particle Imaging)